Ye Qi-Fa, Ruzig Manal Abdel, Gong Nian-Qiao
Institute of Organ Transplantation and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Hepatobiliary Pancreat Dis Int. 2002 Nov;1(4):492-4.
To present a good tacrolimus (FK506) administration protocol in liver transplantation.
Fifty liver transplantation patients were classified into FK506 high-concentration (20 patients), FK506 mid-concentration (20), CsA-FK506 (5) and FK506-CsA (5) groups. Clinical manifestations, FK506 side-effects and pathological changes were observed.
The FK506 high-concentration group showed complications such as infection and liver function damage. The FK506 mid-concentration group showed excellent therapeutic results and some complications easy to deal with.
FK506 is a highly effective immunosuppressive agent and the mid-concentration protocol is a better one.
提出一种肝移植中他克莫司（FK506）的良好给药方案。
将50例肝移植患者分为FK506高浓度组（20例）、FK506中浓度组（20例）、环孢素A - FK506组（5例）和FK506 - 环孢素A组（5例）。观察临床表现、FK506副作用及病理变化。
FK506高浓度组出现感染、肝功能损害等并发症。FK506中浓度组显示出良好的治疗效果且一些并发症易于处理。
FK506是一种高效免疫抑制剂，中浓度给药方案更佳。
